AstraZeneca (LON:AZN – Get Free Report) was upgraded by equities research analysts at Deutsche Bank Aktiengesellschaft to a “hold” rating in a report released on Monday, Digital Look reports.
AZN has been the topic of several other reports. UBS Group cut their target price on AstraZeneca from £107 ($133.20) to GBX 9,900 ($123.24) and set a “sell” rating on the stock in a research note on Monday, February 12th. Jefferies Financial Group reiterated a “hold” rating and set a £110 ($136.94) target price on shares of AstraZeneca in a research note on Friday, February 16th. BMO Capital Markets reiterated an “outperform” rating on shares of AstraZeneca in a research note on Monday, February 12th. Barclays reiterated an “overweight” rating and set a £125 ($155.61) target price on shares of AstraZeneca in a research note on Monday, April 8th. Finally, Berenberg Bank reiterated a “buy” rating on shares of AstraZeneca in a research note on Wednesday, March 13th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and a consensus price target of £115.43 ($143.69).
View Our Latest Report on AstraZeneca
AstraZeneca Stock Performance
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Recommended Stories
- Five stocks we like better than AstraZeneca
- How to buy stock: A step-by-step guide for beginners
- ASML Fires Warning Shot For Tech Investors
- What Are Dividend Achievers? An Introduction
- Prologis Stock Leading U.S. Logistics Boom
- Bank Stocks – Best Bank Stocks to Invest In
- Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.